Savara’s (SVRA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Savara (NASDAQ:SVRA) in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.

A number of other brokerages have also weighed in on SVRA. JMP Securities cut their price objective on Savara from $10.00 to $9.00 and set a market outperform rating for the company in a research report on Tuesday. Oppenheimer lifted their price objective on Savara from $11.00 to $15.00 and gave the stock an outperform rating in a research note on Wednesday, June 26th. Guggenheim upped their price objective on Savara from $8.00 to $10.00 and gave the stock a buy rating in a report on Thursday, June 27th. Finally, Evercore ISI cut their target price on shares of Savara from $10.00 to $7.00 and set an outperform rating for the company in a report on Thursday, May 16th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of Buy and an average target price of $11.17.

Savara Stock Performance

Shares of SVRA stock traded down $0.02 during mid-day trading on Wednesday, reaching $4.24. 76,919 shares of the company’s stock traded hands, compared to its average volume of 1,240,328. Savara has a 12 month low of $3.12 and a 12 month high of $5.70. The firm has a 50 day moving average price of $4.28 and a two-hundred day moving average price of $4.61. The firm has a market capitalization of $585.92 million, a PE ratio of -11.51 and a beta of 1.00. The company has a debt-to-equity ratio of 0.22, a quick ratio of 14.90 and a current ratio of 14.90.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, research analysts forecast that Savara will post -0.41 EPS for the current year.

Hedge Funds Weigh In On Savara

Several large investors have recently modified their holdings of the stock. Affinity Asset Advisors LLC boosted its stake in shares of Savara by 34.5% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,546,850 shares of the company’s stock worth $6,234,000 after purchasing an additional 396,850 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Savara during the second quarter worth approximately $452,000. First Light Asset Management LLC bought a new stake in shares of Savara during the second quarter valued at approximately $8,069,000. Marshall Wace LLP boosted its holdings in shares of Savara by 420.0% in the second quarter. Marshall Wace LLP now owns 304,700 shares of the company’s stock valued at $1,228,000 after purchasing an additional 246,107 shares during the period. Finally, Farallon Capital Management LLC boosted its holdings in shares of Savara by 90.5% in the second quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock valued at $18,377,000 after purchasing an additional 2,165,701 shares during the period. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.